Novel triazole-quinoline derivatives as selective dual binding site acetylcholinesterase inhibitors

Abstract

Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder worldwide. Currently, the only strategy for palliative treatment of AD is to inhibit acetylcholinesterase (AChE) in order to increase the concentration of acetylcholine in the synaptic cleft. Evidence indicates that AChE also interacts with the -amyloid (A ) protein, acting as a chaperone and increasing the number and neurotoxicity of A fibrils. It is known that AChE has two binding sites: the peripheral site, responsible for the interactions with A , and the catalytic site, related with acetylcholine hydrolysis. In this work,we reported the synthesis and biological evaluation of a library of new tacrine-donepezil hybrids,as a potential dual binding site AChE inhibitor, containing a triazole-quinoline system. The synthesis of hybrids was performed in four steps using the click chemistry strategy. These compounds were evaluated as hAChE and hBChE inhibitors, and some derivatives showed IC50 values in themicro-molar range and were remarkably selective towards hAChE. Kinetic assays and molecular modeling studies confirm that these compounds block both catalytic and peripheral AChE sites. These results are quite interesting since the triazole-quinoline system is a new structural scaffold for AChE inhibitors.Furthermore, the synthetic approach is very efficient for the preparation of target compounds, allowing a further fruitful new chemical library optimization.